Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
Date:4/30/2008

e of the program to accelerate

more slowly than had been previously anticipated, in part due to the

increased focus on the ANA598 program, making it less likely that

specific tumor types and a recommended Phase II dose will be identified

during 2008. As a result of this slower pace, the Company expects that

some spending on ANA773 that had been anticipated in 2008 will now be

postponed into 2009.

-- Revised Cash Outlook. Based primarily on the acceleration of ANA598

HCV development activities, partially offset by modestly decreased

spending in 2008 in the ANA773 oncology program, Anadys is revising its

expected net cash utilization for 2008 to be in the range of

$29 million to $31 million.

Webcast of Conference Call

Anadys will host a conference call at 5:00 p.m. EDT today to discuss its first quarter financial results and highlights and to provide an update on its development programs. A live webcast of the call will be available online at http://www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 65984063. The webcast and telephone replay will be available through May 14, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non- nucleoside inhibitor of the NS5b polymerase for the treatment of chronic hepatitis C, and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
3. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
4. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
5. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
6. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
9. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
11. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013  (PSHR) Pacific ... naturally based products across a broad range of ... has retained investor relations firm, BlueWater Advisory Group, ... return to trading process, and to direct the ... initiation. Matthew Mills ...
(Date:5/20/2013)... , May 20, 2013   BioHealth ... focusing on commercializing market-relevant biohealth innovations and increasing ... Maryland , today announced its selection of ... (EIR) for BHI at the National Institutes of ... Institute (NHLBI). Dr. Aiyar will help advance ...
(Date:5/20/2013)... May 20, 2013 Interventional cardiologist Tony ... General Hospital (AGH) Cardiovascular Institute have helped pioneer ... artery disease (CAD) over the past three decades, ... balloon angioplasty and coronary artery stent implantation. , Today, ... play a prominent role in the study of a ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Kitware, a ... visualization tool that enables the exploration of hospital ... created in response to the recent release of “Medicare ... the top 100 most-billed procedures from the Centers for ... costs for similar procedures at hospitals across the country ...
Breaking Biology Technology:Pacific Shore Holdings Retains Investor Relations Firm 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4Kitware Enables Interactive Exploration of CMS Medicare Data 2
... December 3 On,November 28, Essilor cancelled 1,600,000 shares, ... dilutive impact of Oceane bond conversions and,the Company,s stock ... These latest cancellations concerned shares acquired under the 6.9,million ... on July,15, 2008 to offset the dilutive impact of ...
... Dec. 2 Transgenomic,Inc. (OTC Bulletin Board: ... Board: PWRM) today announced that Transgenomic has ... rights for Power3 Medical,s Neurodegenerative,Biomarkers, which include ... disease. Transgenomic plans to offer NuroPro(R) ...
... 2 Bionovo, Inc.,(Nasdaq: BNVI ), a pharmaceutical company ... the areas of women,s health and,cancer, announced that Isaac Cohen, Chairman ... at the 20th Annual Piper Jaffray Health,Care Conference at 8 a.m. ... at,the New York Palace Hotel in New York City. , ...
Cached Biology Technology:Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 2Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 4Bionovo to Present at the Piper Jaffray Healthcare Conference 2
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
(Date:5/17/2013)... in Efficient and Sustainable Global Logistics Operations) is aiming ... the efficiency of intermodal loading systems and the boosting ... 29 European organisations with experience in the logistics sector ... totalling 17,000,000 and a duration of three and a ... develop the semantic components and ontologies shared by the ...
(Date:5/17/2013)... team of scientists using a new X-ray method recorded ... frog embryo in greater detail than ever before., This ... and the search for new treatments for genetic diseases., ... Technologie in Germany, in collaboration with the Advanced Photon ... Laboratory, released the most precise depiction ever of the ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2New logistics services that will cut energy consumption and CO2 emissions 2New X-ray method shows how frog embryos could help thwart disease 2
... birth to develop the ability to determine sunrise and ... of Chicago shows. The research sheds new light ... behaviors, according to Brian Prendergast, associate professor in psychology ... paper published April 27 in the journal PLoS One. ...
... to investigate such things as how Pacific Northwest forests ... by pests and diseases is being pruned back to ... located in a 500-year-old forest near Stevenson in southwest ... Washington, the Forest Service,s Pacific Northwest Research Station and ...
... An international team of scientists, led by researchers at ... have developed a new method for discerning the functions ... functional networks that reveal how gene products interact to ... in the April 29 issue of the journal Cell. ...
Cached Biology News:From the beginning, the brain knows the difference between night and day 2Era of canopy crane ending; certain research and education activities remain 2Era of canopy crane ending; certain research and education activities remain 3As the worm turns, its secrets are revealed 2
...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
RECK (F-20)...
... polyclonal to Peroxiredoxin 1 Peroxiredoxin ... whose mammalian members have been known ... and apoptosis. Many isoforms (about 50 ... amino acid sequence homology, particularly amino-terminal ...
Biology Products: